The Tuberculosis Drug Accelerator at year 10: what have we learned?

Bree B. Aldridge, David Barros-Aguirre, Clifton E. Barry, Robert H. Bates, Steven J. Berthel, Helena I. Boshoff, Kelly Chibale, Xin-Jie Chu, Christopher B. Cooper, Véronique Dartois, Ken Duncan, Nader Fotouhi, Fabian Gusovsky, Philip A. Hipskind, Dale J. Kempf, Joël Lelièvre, Anne J. Lenaerts, Case W. McNamara, Valerie Mizrahi, Carl Nathan (Lead / Corresponding author)David B. Olsen, Tanya Parish, H. Michael Petrassi, Alexander Pym, Kyu Y. Rhee, Gregory T. Robertson, Jeremy Michael Rock, Eric J. Rubin, Betsy Russell, David G. Russell, James C. Sacchettini, Dirk Schnappinger, Michael Schrimpf, Anna M. Upton, Peter Warner, Paul Graham Wyatt, Ying Yuan

Research output: Contribution to journalComment/debatepeer-review

29 Citations (Scopus)


The Tuberculosis Drug Accelerator, an experiment designed to facilitate collaboration in tuberculosis drug discovery by breaking down barriers among competing labs and institutions, has reached a 10-year landmark. We review the consortium’s achievements, advantages and limitations and advocate for the application of similar models to other diseases.
Original languageEnglish
Pages (from-to)1333-1337
Number of pages5
JournalNature Medicine
Early online date5 Jul 2021
Publication statusPublished - Aug 2021


  • Bacterial infection
  • Drug development
  • Drug screening
  • Intellectual-property rights
  • Research management

ASJC Scopus subject areas

  • General Biochemistry,Genetics and Molecular Biology


Dive into the research topics of 'The Tuberculosis Drug Accelerator at year 10: what have we learned?'. Together they form a unique fingerprint.

Cite this